Spots Global Cancer Trial Database for Study of Temzolomide and Gleevec in Advanced Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Temzolomide and Gleevec in Advanced Melanoma
Official Title: Phase I/II Study of Temozolomide and Gleevec (Imatinib Mesylate, Formerly Known as STI571) in Advanced Melanoma
Study ID: NCT00667953
Study Description
Brief Summary: This study has been designed to evaluate the side effects of Gleevec when given in combination with Temzolomide; and to learn more about how these drugs work in the body and whether this combination is useful in treating patients with melanoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact Details
Name: Leslie Fecher, MD
Affiliation: Rogel Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Name: tara mitchell, MD
Affiliation: Abramson CC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
